Skip to main navigation Skip to search Skip to main content

Ferritin in glioblastoma

  • Heidi Jaksch-Bogensperger
  • , Sabine Spiegl-Kreinecker
  • , P Arosio
  • , P Eckl
  • , S Golaszewski
  • , Y Ebner
  • , R Al-Schameri
  • , P Strasser
  • , S. Weis
  • , Nikolaus Bresgen

Research output: Contribution to journal › Article › peer-review

Abstract

Elevated levels of serum ferritin (SF) are observed in several types of cancer; however, little is known on the association between ferritin and glioma, the most frequent type of human primary brain tumour. Here we report that GBM patients show significantly increased pre-surgical SF levels (i.e. ferritinaemia) within the SF reference range and a marked ferritin immunoreactivity of resected tumour tissue. Our findings account for an indirect association between ferritin synthesis in glioma-tissue and altered SF levels, which limits the clinical value of SF as a tumour marker in glioma. Importantly, we show for the first time that GBM-derived glioma cells release ferritin in vitro, which exerts an apoptosis-stimulating activity. Albeit the pathophysiologic context of apoptosis induction by a tumour-derived ferritin remains to be defined, our findings account for a distinct growth-regulatory role of these ferritin species in tumour biology.
Original languageEnglish
Pages (from-to)1441-1444
Number of pages4
JournalBritish Journal of Cancer
Volume122
Issue number10
DOIs
Publication statusPublished - 12 May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fields of science

  • 301 Medical-Theoretical Sciences, Pharmacy

Cite this